Investment Highlights

  • Three ongoing clinical programs
    ⎼ Phase 2 trial treating Prostate Cancer with NIH grant funding
    ⎼ Phase 1 trial in treating Non-Small Cell Lung Cancer –Non-dilutive, Donor funded
    ⎼ Cleared IND for Glioblastoma
  • Strategic relationship with Cedars-Sinai Medical Center (ranked #2 hospital nationally in 2022-2023 US News and World Report) drives clinical trial efficiency (Costs and Enrollment), and streamlines therapeutic innovations
  • Initial clinical development focuses on therapies to overcome cancer drug resistance, derisked with extensive safety studies and biomarker for potential response
  • Extensive therapies to reverse immune suppression in our pipeline
  • Extensive IP portfolio valid until 2035 to 2040
  • Our technologies target a high value, large market - a fast growing $11.3 billion hormone therapy prostate cancer market, $14 billion lung cancer market, and $94 billion immunotherapy market